TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32544361
Drug: bivalent HPV‐16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HPV‐16/18 vaccine with a 1st interval of 51–60 d
Study: 32544361
Drug: bivalent HPV‐16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HPV‐16/18 vaccine with a 2nd interval of 103–139 d
Study: 32544361
Drug: bivalent HPV‐16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HPV‐16/18 vaccine with a 2nd interval of 140–160 d
Study: 32544361
Drug: bivalent HPV‐16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HPV‐16/18 vaccine with a 2nd interval of 161–198 d
Study: 32115477
Drug: Nalmefene 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 20 mg
Study: 32145041
Drug: morphine-naloxone 100:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine-naloxone 100:1 (75 mg: 0.75 mg)
Study: 32145041
Drug: morphine-naloxone 200:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine-naloxone 200:1 (75 mg: 0.375 mg)
Study: 32145041
Drug: morphine mono
Normalized name: Morphine monomethyl ether
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine mono (75 mg)
Study: 33279603
Drug: Enteric-coated fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated fast release formulation
Study: 33058774
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) dexamethasone
Study: 35380237
Drug: Control (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Treatment as Usual, TAUG, n = 8)
Study: 32212354
Drug: Oral Feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Feeding (OF)
Study: 34077509
Drug: Risankizumab 180
Normalized name: RISANKIZUMAB 180 mg in 1.2 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 180 mg every 8 weeks
Study: 34077509
Drug: Risankizumab 600
Normalized name: RISANKIZUMAB 600 mg in 10 mL INTRAVENOUS INJECTION [Skyrizi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 600 mg every 4 weeks (for reinduction of four patients)
Study: 34125259
Drug: i-gel laryngeal
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel laryngeal mask airway
Study: 35514364
Drug: Home-based NMES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based NMES therapy
Study: 33909052
Drug: Informed consent
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Informed consent documents from COVID-19 vaccine trials
Study: 32591433
Drug: ChAdOx1-MVA 5T4
Normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1-MVA 5T4 vaccine
Study: 33078646
Drug: Multi-vitamin-mineral supplement
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-vitamin-mineral supplement (MVMS)
Study: 32538835
Drug: Increased serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased serum calcium level (per 1 standard deviation (SD) increase 0.5 mg/dL)
Study: 34271963
Drug: Single-agent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent oral selinexor
Study: 32535481
Drug: Abelmoschus manihot
Normalized name: ABELMOSCHUS MANIHOT WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abelmoschus manihot (AM) 2.5 g three times per day for 48 weeks
Study: 32535481
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: losartan potassium 100 mg per day for 48 weeks
Study: 34636000
Drug: Upadacitinib monotherapy
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib monotherapy
Study: 35919945
Drug: Upadacitinib plus
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib plus csDMARD therapy
Study: 35919945
Drug: csDMARD-only therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: csDMARD-only therapy
Study: 35919945
Drug: bDMARD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bDMARD plus csDMARD therapy
Study: 33257661
Drug: 10-mg oral
Normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-mg oral methotrexate once weekly with daily 5-mg folic acid for 12 weeks
Study: 33257661
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo with daily 5-mg folic acid for 12 weeks
Study: 32139496
Drug: Nurse-delivered sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-delivered sleep restriction therapy (SRT) plus sleep hygiene booklet
Study: 33556413
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg/day (n = 32)
Study: 33556413
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg/day (n = 32) in statin non-users
Study: 35184326
Drug: Low-dose aripiprazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aripiprazole adjunctive to antidepressant therapy
Study: 33429750
Drug: Bosentan combined
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan combined with vardenafil oral group
Study: 33429750
Drug: Vardenafil oral
Normalized name: vardenafil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil oral group
Study: 36272432
Drug: Molnupiravir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir (800 mg orally, twice daily for 5 days)
Study: 34399982
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium nitrate (700 mg×2)
Study: 33139276
Drug: Tribendimidine monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine monotherapy
Study: 33232172
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose pill)
Study: 33075067
Drug: Intensive MDA
Normalized name: BK-MDA
DrugBank: BK-MDA (DB12809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive MDA (quarterly single-dose praziquantel 40mg/kg; triple-dose albendazole 400mg)
Study: 33075067
Drug: Standard Uganda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Uganda government intervention (annual single-dose praziquantel 40mg/kg; 6-monthly single-dose albendazole)
Study: 34086129
Drug: Distrust of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distrust of vaccine safety and general vaccine avoidance
Study: 32085633
Drug: Birch pollen
Normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch pollen immunotherapy
Study: 34966141
Drug: Azithromycin at
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin at 10 mg/kg/d
Study: 34966141
Drug: Doxycycline at
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline at 4.4 mg/kg/d for 5 days
Study: 35732989
Drug: hBO‐HD (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: hBO‐HD (640 mg)
Study: 35732989
Drug: hBO‐MD (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: hBO‐MD (320 mg)
Study: 35732989
Drug: hBO‐LD (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: hBO‐LD (160 mg)
Study: 36239756
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks, followed by alendronate for 48 weeks
Study: 32789966
Drug: Raltitrexed (RTX)
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed (RTX) 2 mg/m2 every 2 weeks
Study: 32789966
Drug: Raltitrexed (RTX)
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed (RTX) 3 mg/m2 every 3 weeks
Study: 32152817
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine lymphedema treatments)
Study: 33858397
Drug: Hemoglobin concentration
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin concentration (g/dL)
Study: 33428786
Drug: Hyperthermic intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin (460 mg/m2) and docetaxel (in escalating doses) after preoperative systemic chemotherapy and surgical procedure.
Study: 33155417
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (specific drug not mentioned)
Study: 33155417
Drug: Censoring at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Censoring at initiation of subsequent therapy
Study: 33155417
Drug: Considering recurrence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Considering recurrence or progression events (including death) before and after initiation of subsequent therapy
Study: 33155417
Drug: Considering the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Considering the start of subsequent therapy as an event
Study: 32618265
Drug: Mass Drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Drug Administration (MDA) with dihydroartemisinin‐piperaquine (DHAP)
Study: 33340154
Drug: Medical grade
Normalized name: Skarcade Medical Grade Silicone Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical grade honey gel (L-Mesitran Soft®) applied intraoperatively on the linea alba
Study: 33340154
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medical grade honey gel)
Study: 33340154
Drug: Medical grade
Normalized name: Skarcade Medical Grade Silicone Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical grade honey gel (L-Mesitran Soft®)
Study: 34547261
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg tablet dissolved in apple juice)
Study: 34547261
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL of apple juice)
Study: 36301338
Drug: Daratumumab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 16 mg/kg
Study: 33388991
Drug: Turbinate outfracture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbinate outfracture in combination with radiofrequency ablation
Study: 33833225
Drug: Psilocybin (0.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (0.17 mg/kg)
Study: 32701929
Drug: Leukocyte‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte‐ and platelet‐rich fibrin (L‐PRF) used to fill and cover extraction sockets (n=11, Test Group)
Study: 32701929
Drug: No L‐PRF
Approvals — FDA: no, EMA: no, PMDA: no
Description: No L‐PRF used (n=12, Control Group)
Study: 38674803
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 6 months
Study: 35708992
Drug: Solution‐Focused Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution‐Focused Group Psychoeducation
Study: 33293316
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II type 1 receptor blockers (ARBs)
Study: 34228172
Drug: Self-reported symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported symptoms after treatment
Study: 32278781
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of immediate-release venlafaxine
Study: 34138909
Drug: Antibody titer
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody titer testing
Study: 33026175
Drug: 160 IU
Normalized name: Ascorbic Acid/Copper/Vitamin A/Vitamin E/Zinc 113 MG-0.4 MG-7160 IU-100 IU-17.4 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 IU intranasal insulin (IN-INS)
Study: 36092515
Drug: Gum Arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum Arabic (GA) powder, applied twice a day for 60 days.
Study: 36092515
Drug: Microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose powder (placebo), applied twice a day for 60 days.
Study: 32438420
Drug: Sham interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham interventions (e.g., saline injections into spinal structures, peripheral nerves, cranial surgery, spine surgery)
Study: 37077927
Drug: 2.5% BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% BPO gel
Study: 32205769
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic treatment (ABT) per PEG protocol (n=78)
Study: 32706674
Drug: Self-directed web-based
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed web-based education and exercise therapy for 6 weeks
Study: 32706674
Drug: Physiotherapist-led education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapist-led education and exercise therapy (face-to-face or telerehabilitation) for 12 weeks
Study: 33782552
Drug: Pharmacogenetic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic testing for medications managing acute and chronic pain and depression
Study: 33509394
Drug: Hemoglobin drop
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin drop (minor: ≥3 and <5 g/dl) without overt bleeding
Study: 33509394
Drug: Hemoglobin drop
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin drop (major: ≥5 g/dl) without overt bleeding
Study: 33509394
Drug: Hemoglobin drop
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin drop (minor: ≥3 and <5 g/dl) with overt bleeding
Study: 33509394
Drug: Hemoglobin drop
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin drop (major: ≥5 g/dl) with overt bleeding
Study: 35577476
Drug: Systemic lidocaine
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic lidocaine (1.5 mg/kg bolus, followed by 1.5 mg/kg/hour infusion until the end of surgery)
Study: 33615769
Drug: Electric toothbrush/irrigator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electric toothbrush/irrigator combination (test)
Study: 32807241
Drug: LMWH +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH + steroid group
Study: 32807241
Drug: UFH +
Normalized name: Unfractionated Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UFH + steroid group
Study: 36206400
Drug: Belimumab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (1, 4, or 10 mg/kg intravenous or 200 mg subcutaneous) plus standard therapy
Study: 32131611
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg low-dose aspirin (COX-1 inhibitor) for 2 weeks
Study: 33492500
Drug: Oral hydrocortisone
Normalized name: hydrocortisone Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrocortisone sodium succinate and aluminum phosphate gel (OHA)
Study: 33492500
Drug: Endoscopic loco-regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic loco-regional triamcinolone acetonide injection (ETI) plus oral prednisone
Study: 33492500
Drug: ETI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETI plus oral prednisone
Study: 34455688
Drug: Prehospital antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital antiplatelet therapy
Study: 34455688
Drug: Non-antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antiplatelet therapy
Study: 32372486
Drug: Nitrate treatment
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate treatment (various preparations and doses)
Study: 32372486
Drug: Nitrate treatment
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate treatment (pooled active treatment groups)
Study: 35860190
Drug: Shenling Chengqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenling Chengqi decoction combined with routine treatment for 7 days
Study: 33105277
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia of 20% sevoflurane emulsion
Study: 33105277
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia of sevoflurane
Study: 35112178
Drug: Local periarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local periarticular infiltration anaesthesia (LIA) with 60 ml of ropivacaine 0.5% and 1 ml of dexmedetomidine (100 µg ml‐1)
Study: 35112178
Drug: Ultrasound-guided regional
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided regional anaesthesia (USRA) with two single-shot femoral and popliteal blocks, each with 15 ml of ropivacaine 0.5% and 0.5 ml of dexmedetomidine
Study: 33784802
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 2.5 mg
Study: 33784802
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 5 mg
Study: 35439347
Drug: Rezafungin 10
Normalized name: Rezafungin
DrugBank: Rezafungin (DB16310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezafungin 10 mg single subcutaneous dose
Study: 35439347
Drug: Rezafungin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezafungin (various doses: 1, 10, 30, 60, 100, or 200 mg)
Study: 33706186
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of perindopril, indapamide, and amlodipine
Study: 35283313
Drug: ChAdOx1 followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ChAdOx1 followed by a mRNA vaccine
Study: 33337904
Drug: Psychological behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological behaviour management programme (including symbolic modelling, tell‐show‐do, positive reinforcement, distraction) during the second treatment
Study: 33337904
Drug: Watching cartoon
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watching cartoon animations during the first treatment and control group during the second treatment
Study: 35293006
Drug: D‐VCd followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐VCd followed by daratumumab monotherapy
Study: 33285469
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg intravenously every 2 weeks for up to 12 months)
Study: 34449185
Drug: Abbreviated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated therapy (1 month of dual antiplatelet therapy)
Study: 34449185
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (continuation of dual antiplatelet therapy for at least 2 additional months)
Study: 35713517
Drug: Pyrotinib and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib and trastuzumab with weekly paclitaxel-cisplatin neoadjuvant chemotherapy for four cycles
Study: 34927293
Drug: M100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: M100 (100 g ML powder per sow per day)
Study: 34927293
Drug: M200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: M200 (200 g ML powder per sow per day)
Study: 34927293
Drug: M300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: M300 (300 g ML powder per sow per day)
Study: 34927293
Drug: M400 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: M400 (400 g ML powder per sow per day)
Study: 34927293
Drug: C (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (control group, 0 g ML powder per sow per day)
Study: 34668795
Drug: Multimodal nonopioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal nonopioid analgesic protocol (acetaminophen, ketorolac, diazepam, gabapentin, and meloxicam)
Study: 34668795
Drug: Standard opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard opioid regimen (hydrocodone‐acetaminophen)
Study: 34391876
Drug: Multimodal nonopioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal nonopioid analgesic protocol
Study: 35331859
Drug: NSAID (loxoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (loxoprofen sodium, 180 mg/day for 5 weeks)
Study: 33407791
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of 5 ml isotonic saline every second week for a total of 4 injections
Study: 34473194
Drug: Ensartinib, 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensartinib, 225 mg once daily
Study: 34473194
Drug: Crizotinib, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib, 250 mg twice daily
Study: 33180670
Drug: AS04-adjuvanted HPV-16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS04-adjuvanted HPV-16/18 vaccine
Study: 34764183
Drug: 6-week twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week twice-weekly regimen of rifapentine plus isoniazid
Study: 34672928
Drug: 1-day acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day acceptance and commitment therapy (ACT) workshop
Study: 36916653
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus (TAC)
Study: 33542412
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 (HG)
Study: 32482355
Drug: 0.2 μg.kg−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg.kg−1 remifentanil combined with propofol